Aortoiliac Occlusive Disease

No Results

No Results


In patients with peripheral arterial disease (PAD), obstructing plaques caused by atherosclerotic occlusive disease commonly occur in the infrarenal aorta and iliac arteries. Atherosclerotic plaques may induce symptoms either by obstructing blood flow or by breaking apart and embolizing atherosclerotic and/or thrombotic debris to more distal blood vessels. If the plaques are large enough to impinge on the arterial lumen, reduction of blood flow to the extremities occurs.

Several risk factors exist for development of the arterial lesions, and recognition of these factors enables physicians to prescribe nonoperative treatment that may alleviate symptoms as well as prolong life.

Aortoiliac occlusive disease (AIOD) occurs commonly in patients with PAD. Significant lesions in the aortoiliac arterial segment are exposed easily by palpation of the femoral pulses. Any diminution of the palpable femoral pulse indicates that a more proximal obstruction exists.

Obstructive lesions may be present in the infrarenal aorta, common iliac artery, internal iliac (hypogastric) artery, external iliac artery, or combinations of any or all of these vessels. Occasionally, degenerated nonstenotic atheromatous disease exists in these vessels and may manifest by atheroembolism to the foot, the “blue toe” or “trash foot” syndrome. Generally, patients with aortoiliac PAD have a poorer general prognosis than those with more distal PAD. [1]

Before prosthetic grafts for aortic bypasses became available, the first direct surgical reconstructions on the aorta were performed using the technique of thromboendarterectomy (TEA), first described by Dos Santos of Lisbon in 1947. [2] The initial procedure was performed on a patient with superficial femoral artery (SFA) obstruction, and Dos Santos termed the procedure disobliteration. Wylie adapted this technique to the aortoiliac region and, in 1951, performed the first aortoiliac endarterectomy in the United States. [3]

With the discovery of suitable prosthetic graft materials for aortic replacement in the 1960s, surgical treatment of AIOD became available to even more patients.

In 1964, Dotter first performed percutaneous iliac angioplasty using a coaxial system of metal dilators. [4] This procedure proved to have limited application, because of the cumbersome nature of the device. However, Dotter’s early work paved the way for Grüntzig, who, in 1974, developed a catheter with an inflatable polyvinyl chloride balloon that could be passed over a guide wire. [5] This device became the cornerstone for the percutaneous treatment of arterial occlusive lesions today.

In 1985, Palmaz introduced the first stent that helped to improve the results of angioplasty for arterial occlusive disease. [6] Since the advent of angioplasty and stenting, the technology has evolved at an astronomic rate. The design and quality of endovascular devices, as well as the ease and accuracy of performing the procedures, have improved. These improvements have led to improved patient outcomes following endovascular interventions for AIOD.

Surgical treatment of AIOD has been well standardized for many years, and the outcomes are quite good. However, the additional techniques of percutaneous transluminal angioplasty (PTA) and stenting have provided more alternatives to open surgery and make successful approaches available to patients who may have been considered at an unacceptably high risk for conventional open surgical repairs.

Catheter-based endovascular treatments for AIOD offer the advantages of less morbidity, faster recovery, and shorter hospital stays. In fact, most endovascular interventions today are simply performed as outpatient procedures.

This article reviews the risk factors for development of atherosclerotic occlusive disease of the aorta and iliac arteries and describes the natural history, diagnosis, and treatment of the disease.

For patient education resources, see the Cholesterol Center, as well as High Cholesterol and Cholesterol FAQs.

Atherosclerosis is an extraordinarily complex degenerative disease with no known single cause. However, many variables are known to contribute to the development of atherosclerotic lesions. One popular theory emphasizes that atherosclerosis occurs as a response to arterial injury. Factors that are known to be injurious to the arterial wall include the following:

Lipid accumulation begins in the smooth-muscle cells and macrophages that occur as an inflammatory response to endothelial injury, and the “fatty streak” begins to form in the arterial wall. The atheroma consists of differing compositions of cholesterol, cholesterol esters, and triglycerides. Some plaques are unstable, and fissures occur on the surface of the plaque that expose the circulating platelets to the inner elements of the atheroma.

Platelet aggregation then is stimulated. Platelets bind to fibrin through activation of the glycoprotein (GP) IIb/IIIa receptor on the platelets, and a fresh blood clot forms in the area of plaque breakdown. These unstable plaques are prone to atheromatous embolization and/or propagation of clot that eventually can occlude the arterial lumen.

If the atheroma enlarges enough to occupy at least 50% of the arterial lumen, the flow velocity of blood through that stenosis can significantly increase. The oxygen requirements of the lower extremity at rest are low enough that even with a moderate proximal stenosis, no increase in blood flow velocity occurs. During exercise, however, the oxygen debt that occurs in ischemic muscle cannot be relieved, because of the proximal obstruction of blood flow; this results in claudication symptoms.

In more advanced cases, critical tissue ischemia occurs, and neuropathic rest pain or tissue loss ensues. However, critical limb ischemia (CLI) is seldom, if ever, caused by AIOD alone. Commonly, in patients with CLI, multiple arterial segments are involved in the occlusive atherosclerotic process.

Three distinct arterial segments distal to the visceral bearing portion of the abdominal aorta may become diseased by atherosclerosis, as follows:

Diabetes mellitus is a risk factor that results in a characteristic pattern of atherosclerotic lesions in patients with PAD. The proximal inflow vessels (aorta, iliac arteries) tend be normal. However, the femoropopliteal segment (including the deep femoral artery), and especially the proximal tibial arteries, are usually severely diseased. Fortunately, the distal tibial and plantar vessels may be normal, enabling successful arterial reconstruction for limb-threatening ischemia.

Atherosclerosis is the most common cause of occlusive plaques in the aorta and iliac arteries. Several risk factors exist for the development of atherosclerotic plaques in the aortoiliac arterial segment. Cigarette smoking and hypercholesterolemia are observed more commonly in patients with AIOD than in those with infrainguinal occlusive disease. In addition, patients with AIOD tend to be younger and less likely to have diabetes.

An uncommon cause of aortic obstruction is Takayasu disease, a nonspecific arteritis that may cause obstruction of the abdominal aorta and its branches. The etiology of Takayasu disease is not known. For the purposes of this article, only occlusive lesions caused by atherosclerosis are considered.

At least 50% of patients with PAD have no symptoms, and therefore, the exact incidence and prevalence of the condition is unknown. However, the incidence of PAD is known to increase with advancing age, so that by age 70 years, as much as 25% of the US population is affected. Occlusive disease involving the aortoiliac arterial segment occurs commonly in patients with PAD and is second only to occlusive disease of the SFA in frequency.

Outcomes after aortic operations for AIOD are measured in terms of operative mortality and patency of the arterial reconstruction over time. These outcomes are similar for aortoiliac TEA and aortofemoral bypass (AFB). The 30-day operative mortality is 2-3%. Long-term patency is excellent too: 85-90% at 5 years after AFB or TEA. If patients continue to smoke, however, these excellent patency rates are reduced by half.

Outcomes for extra-anatomic (axillofemoral or femorofemoral) bypasses are clearly not as good as those for either AFB or aortoiliac TEA. Operative mortality might be expected to be better for extra-anatomic bypass than for AFB because of the extracavitary nature of these procedures and the absence of the requirement for aortic occlusion during the operation. However, the operative mortality (0-4% for femorofemoral bypass; 2-11% for axillobifemoral bypass) reflects the selected patients in whom these procedures are performed. The 5-year primary patency rate with extra-anatomic bypass for AIOD is 19-50% for axillobifemoral bypass and 44-85% for femorofemoral bypass.

In a study of 92 patients with AIOD who underwent AFB (n=72), aortioiliac bypass (n=15), or both (n=5), Lee et al reported overall primary patency rates of 86.2% at 5 years and 77.6% at 10 years, [7] as well as a 10-year limb salvage rate of 97.7% and an overall survival rate of 91.7%.

Endovascular techniques (ie, PTA and stent placement) offer alternatives to conventional surgical repair. Therefore, understanding the outcomes offered with such interventions is important.

Although isolated stenosis of the infrarenal aorta or common iliac artery is uncommon, this lesion is suited ideally to PTA, stent placement, or both. For localized segmental occlusive disease in the aorta, PTA can achieve initial technical success rates of 95%, with 5-year patency rates of 80-87%. For iliac lesions, PTA yields initial success rates of 93-97%, with 5-year patency rates of 54-85%. These results seem to be improved when arterial stents are used either primarily or as an adjunct to PTA for the treatment of iliac artery stenosis.

One study investigating the effects of heavy calcification in stent-implanted iliac arteries showed that iliac stents in heavily calcified lesions presented significant residual stenosis; however, even in cases with incomplete expansion of the stent, further blockage was not found, and all stents remained anatomically patent. [8]

In a systematic review and meta-analysis designed to examine the clinical outcomes of endovascular and open bypass treatment for AIOD, Indes et al found that endovascular treatment was associated with shorter hospital stays, lower complication rates, and reduced 30-day mortality, whereas open bypass was associated with higher primary and secondary patency rates at 1, 3, and 5 years. [9]

Aboyans V, Desormais I, Lacroix P, Salazar J, Criqui MH, Laskar M. The general prognosis of patients with peripheral arterial disease differs according to the disease localization. J Am Coll Cardiol. 2010 Mar 2. 55(9):898-903. [Medline].

Dos Santos JC. Sur la desobstruction des thrombus arterielles anciennes. Mem Acad Chir. 1947. 73:409.

Wylie EJ. Thromboendarterectomy for arteriosclerotic thrombosis of major arteries. Surgery. 1952. 23:275-292. [Medline].

Dotter C, Judkins M. Transluminal treatment of arteriosclerotic obstruction: Description of a new technique and a preliminary report of its application. Circulation. 1964 Nov. 30:654-70. [Medline].

Grüntzig A, Hopff H. [Percutaneous recanalization after chronic arterial occlusion with a new dilator-catheter (modification of the Dotter technique) (author’s transl)]. Dtsch Med Wochenschr. 1974 Dec 6. 99(49):2502-10, 2511. [Medline].

Palmaz JC, Sibbitt RR, Reuter SR, et al. Expandable intraluminal graft: a preliminary study. Work in progress. Radiology. 1985 Jul. 156(1):73-7. [Medline].

Lee GC, Yang SS, Park KM, Park Y, Kim YW, Park KB, et al. Ten year outcomes after bypass surgery in aortoiliac occlusive disease. J Korean Surg Soc. 2012 Jun. 82(6):365-9. [Medline]. [Full Text].

Chang IS, Park KB, Do YS, Park HS, Shin SW, Cho SK, et al. Heavily calcified occlusive lesions of the iliac artery: long-term patency and CT findings after stent placement. J Vasc Interv Radiol. 2011 Aug. 22 (8):1131-7.e1. [Medline].

Indes JE, Pfaff MJ, Farrokhyar F, Brown H, Hashim P, Cheung K, et al. Clinical outcomes of 5358 patients undergoing direct open bypass or endovascular treatment for aortoiliac occlusive disease: a systematic review and meta-analysis. J Endovasc Ther. 2013 Aug. 20 (4):443-55. [Medline].

[Guideline] American Diabetes Association. 6. Glycemic targets. Diabetes Care. 2017 Jan. 40 (Suppl 1):S48-S56. [Medline]. [Full Text].

Ahmed S, Raman SP, Fishman EK. CT angiography and 3D imaging in aortoiliac occlusive disease: collateral pathways in Leriche syndrome. Abdom Radiol (NY). 2017 Apr 11. [Medline].

[Guideline] Society for Vascular Surgery Lower Extremity Guidelines Writing Group, Conte MS, Pomposelli FB, Clair DG, Geraghty PJ, McKinsey JF, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg. 2015 Mar. 61 (3 Suppl):2S-41S. [Medline]. [Full Text].

Helgetveit I, Krog AH. Totally laparoscopic aortobifemoral bypass surgery in the treatment of aortoiliac occlusive disease or abdominal aortic aneurysms – a systematic review and critical appraisal of literature. Vasc Health Risk Manag. 2017. 13:187-199. [Medline]. [Full Text].

Weitz JI, Byrne J, Clagett GP. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation. 1996 Dec 1. 94(11):3026-49. [Medline].

Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA. 1995 Sep 27. 274(12):975-80. [Medline].

Blaisdell FW, Hall AD. Axillary femoral bypass for lower extremity ischemia. Surgery. 1963. 54:563. [Medline].

Iida O, Soga Y, Takahara M, Kawasaki D, Yamauchi Y, Suzuki K, et al. Efficacy of the S.M.A.R.T. Control vs. Other Stents for Aortoiliac Occlusive Disease in Contemporary Clinical Practice. J Endovasc Ther. 2013 May. 20(3):431-9. [Medline].

Goverde PC, Grimme FA, Verbruggen PJ, Reijnen MM. Covered endovascular reconstruction of aortic bifurcation (CERAB) technique: a new approach in treating extensive aortoiliac occlusive disease. J Cardiovasc Surg (Torino). 2013 Jun. 54(3):383-7. [Medline].

Ichihashi S, Higashiura W, Itoh H, Sakaguchi S, Nishimine K, Kichikawa K. Long-term outcomes for systematic primary stent placement in complex iliac artery occlusive disease classified according to Trans-Atlantic Inter-Society Consensus (TASC)-II. J Vasc Surg. 2011 Apr. 53(4):992-9. [Medline].

Van Haren RM, Goldstein LJ, Velazquez OC, Karmacharya J, Bornak A. Endovascular treatment of TransAtlantic Inter-Society Consensus D aortoiliac occlusive disease using unibody bifurcated endografts. J Vasc Surg. 2017 Feb. 65 (2):398-405. [Medline].

Küffer G, Spengel F, Steckmeier B. Percutaneous reconstruction of the aortic bifurcation with Palmaz stents: case report. Cardiovasc Intervent Radiol. 1991 May-Jun. 14 (3):170-2. [Medline].

Groot Jebbink E, Holewijn S, Slump CH, Lardenoije JW, Reijnen MMPJ. Systematic Review of Results of Kissing Stents in the Treatment of Aortoiliac Occlusive Disease. Ann Vasc Surg. 2017 Jul. 42:328-336. [Medline].

Mwipatayi BP, Thomas S, Wong J, Temple SE, Vijayan V, Jackson M, et al. A comparison of covered vs bare expandable stents for the treatment of aortoiliac occlusive disease. J Vasc Surg. 2011 Dec. 54 (6):1561-70. [Medline].

Groot Jebbink E, Grimme FA, Goverde PC, van Oostayen JA, Slump CH, Reijnen MM. Geometrical consequences of kissing stents and the Covered Endovascular Reconstruction of the Aortic Bifurcation configuration in an in vitro model for endovascular reconstruction of aortic bifurcation. J Vasc Surg. 2015 May. 61 (5):1306-11. [Medline].

Maldonado TS, Westin GG, Jazaeri O, Mewissen M, Reijnen MM, Dwivedi AJ, et al. Treatment of Aortoiliac Occlusive Disease with the Endologix AFX Unibody Endograft. Eur J Vasc Endovasc Surg. 2016 Jul. 52 (1):64-74. [Medline].

Khanjan H Nagarsheth, MD, MBA Assistant Professor of Surgery, Department of Vascular Surgery, University of Maryland Medical System

Khanjan H Nagarsheth, MD, MBA is a member of the following medical societies: Academic Surgical Congress, American College of Surgeons, American Venous Forum, Association of Trauma and Military Surgery, Eastern Association for the Surgery of Trauma, Eastern Vascular Society, Knoxville Academy of Medicine, Society for Clinical Vascular Surgery, Society for Vascular Surgery, Society of American Gastrointestinal and Endoscopic Surgeons, Society of Critical Care Medicine, Southeastern Surgical Congress, Tennessee Medical Association, Vascular Society of New Jersey

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Vincent Lopez Rowe, MD Professor of Surgery, Program Director, Vascular Surgery Residency, Department of Surgery, Division of Vascular Surgery, Keck School of Medicine of the University of Southern California

Vincent Lopez Rowe, MD is a member of the following medical societies: American College of Surgeons, American Surgical Association, Pacific Coast Surgical Association, Society for Clinical Vascular Surgery, Society for Vascular Surgery, Western Vascular Society

Disclosure: Nothing to disclose.

Kenneth E McIntyre, Jr, MD Professor of Surgery, Chief, Division of Vascular Surgery, University of Nevada School of Medicine; Chief, Surgical Service, Chief, Vascular Surgery, Veterans Administration of Southern Nevada

Kenneth E McIntyre, Jr, MD is a member of the following medical societies: Society for Vascular Surgery, Southern Association for Vascular Surgery, Society for Clinical Vascular Surgery, American College of Surgeons

Disclosure: Nothing to disclose.

Jeffrey Lawrence Kaufman, MD Associate Professor, Department of Surgery, Division of Vascular Surgery, Tufts University School of Medicine

Jeffrey Lawrence Kaufman, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Surgeons, American Society for Artificial Internal Organs, Association for Academic Surgery, Association for Surgical Education, Massachusetts Medical Society, Phi Beta Kappa, Society for Vascular Surgery

Disclosure: Nothing to disclose.

Aortoiliac Occlusive Disease

Research & References of Aortoiliac Occlusive Disease|A&C Accounting And Tax Services

Leave a Reply